# Metformin Continuation Versus Interruption Following Coronary Angiography: a Pilot Randomized Controlled Trial

Study · id `cardio:ct-nct03980990` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03980990](<https://clinicaltrials.gov/study/NCT03980990>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03980990

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.

## Technical summary

Registry record NCT03980990. Randomized; no masking; primary purpose treatment. Start 2019-06-17 (actual); primary completion 2020-06-17 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 500 participants (planned count; ClinicalTrials.gov record NCT03980990, source copy `cardio:ctgov-nct03980990-2019-06-20`, retrieved 2026-10-26)
- Started: 2019-06-17 (actual) (ClinicalTrials.gov record NCT03980990, source copy `cardio:ctgov-nct03980990-2019-06-20`, retrieved 2026-10-26)
- Primary completion: 2020-06-17 (anticipated) (ClinicalTrials.gov record NCT03980990, source copy `cardio:ctgov-nct03980990-2019-06-20`, retrieved 2026-10-26)
- Completion: 2020-06-17 (anticipated) (ClinicalTrials.gov record NCT03980990, source copy `cardio:ctgov-nct03980990-2019-06-20`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT03980990, source copy `cardio:ctgov-nct03980990-2019-06-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03980990-2019-06-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Metformin Continuation Versus Interruption Following Coronary Angiography: a Pilot Randomized Controlled Trial
- Condition: Acute Coronary Syndrome
- Condition: Unstable Angina
- Condition: Diabetes Mellitus
- Condition: Metformin Adverse Reaction
- Intervention (Drug): Metformin
- Lead sponsor: University of Saskatchewan
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Unstable angina (`cardio:unstable-angina`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: University of Saskatchewan (`cardio:org-university-of-saskatchewan`)

## Provenance

Content hash: 0d407bde1ae0582b07226e1b9758b9242392b698d324c4c304575cee7a881adc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
